|
Phathom Pharmaceuticals Inc (PHAT) |
|
|
|
PHAT's Capital Expenditures Growth by Quarter and Year
Phathom Pharmaceuticals Inc 's Capital Expenditures results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
Capital Expenditures Growth Y/Y▼
|
Capital Expenditures Growth Y/Y▼
|
PHAT Capital Expenditures (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
IV Quarter |
December |
-
|
0.41
|
0.10
|
0.12
|
III Quarter |
September |
0.94
|
0.13
|
0.01
|
0.18
|
II Quarter |
June |
0.01
|
0.43
|
0.05
|
0.06
|
I Quarter |
March |
0.21
|
0.07
|
0.17
|
0.68
|
FY |
|
1.16
|
1.04
|
0.33
|
1.04
|
PHAT Capital Expenditures third quarter 2023 Y/Y Growth Comment |
Phathom Pharmaceuticals Inc achieved in the third quarter 2023, above Company average Capital Expenditures surge of 622.31% year on year, to $ 0.94 millions.
Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Capital Expenditures growth. While Phathom Pharmaceuticals Inc ' s Capital Expenditures doubling of 622.31% ranks overall at the positon no. 776 in the third quarter 2023.
|
PHAT Capital Expenditures ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
IV Quarter |
December |
- |
310 % |
-16.67 % |
9.09 % |
III Quarter |
September |
622.31 % |
1200 % |
-94.44 % |
500 % |
II Quarter |
June |
-97.67 % |
760 % |
-16.67 % |
- |
I Quarter |
March |
200 % |
-58.82 % |
-75 % |
- |
FY |
|
- |
215.15 % |
-68.27 % |
642.86 % |
PHAT Capital Expenditures (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
IV Quarter |
December |
- |
215.38 % |
900 % |
-33.33 % |
III Quarter |
September |
9290 % |
-69.77 % |
-80 % |
200 % |
II Quarter |
June |
-95.24 % |
514.29 % |
-70.59 % |
-91.18 % |
I Quarter |
March |
-48.78 % |
-30 % |
41.67 % |
518.18 % |
FY (Year on Year) |
|
- |
215.15 % |
-68.27 % |
642.86 % |
Capital Expenditures Y/Y Growth Statistics |
High |
Average |
Low |
687.88 % |
111.97 % |
-68.46 % |
(Dec 31 2020) |
|
(Dec 31 2021) |
|
Capital Expenditures Y/Y Growth Statistics |
High |
Average |
Low |
687.88 % |
111.97 % |
-68.46 % |
(Dec 31 2020) |
|
(Dec 31 2021) |
|
Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Phathom Pharmaceuticals Inc 's Q/Q Capital Expenditures Growth
Capital Expenditures Q/Q Growth Statistics |
High |
Average |
Low |
15550 % |
1093.77 % |
-97.2 % |
(Sep 30 2023) |
|
|
PHAT's III. Quarter Q/Q Capital Expenditures Comment |
Phathom Pharmaceuticals Inc achieved in the III. Quarter 2023 above company average sequential Capital Expenditures doubling of 9290%, to $ 0.94 millions, from $0.01 millions in the second quarter. PHAT is undergoing a remarkable growth, not only claiming above normal gain, but also increasing rate, Nora Jansson, Major Pharmaceutical Preparations industry observer located in Boston mentioned.
Within Major Pharmaceutical Preparations industry Phathom Pharmaceuticals Inc achieved highest sequential Capital Expenditures growth. While Phathom Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 9. |
|
|
Capital Expenditures Q/Q Growth Statistics |
High |
Average |
Low |
15550 % |
1093.77 % |
-97.2 % |
(Sep 30 2023) |
|
|
PHAT's III. Quarter Q/Q Capital Expenditures Comment |
Phathom Pharmaceuticals Inc achieved in the III. Quarter 2023 above company average sequential Capital Expenditures doubling of 9290%, to $ 0.94 millions, from $0.01 millions in the second quarter. Phathom Pharmaceuticals Inc is going from strength to strength, not just reporting better then normal gain, but also increasing speed, Nora Jansson, Major Pharmaceutical Preparations industry observer located in Boston said.
Within Major Pharmaceutical Preparations industry Phathom Pharmaceuticals Inc achieved highest sequential Capital Expenditures growth. While Phathom Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 9. |
|
Phathom Pharmaceuticals Inc 's 12 Months Capital Expenditures Growth Year on Year
Capital Expenditures TTM Growth |
12 Months Ending (Sep 30 2023) |
12 Months Ending (Jun 30 2023) |
12 Months Ending (Mar 31 2023) |
12 Months Ending (Dec 31 2022) |
12 Months Ending (Sep 30 2022) |
Cumulative Capital Expenditures 12 Months Ending |
$ 1.57 |
$ 0.77 |
$ 1.19 |
$ 1.04 |
$ 0.73 |
Y / Y Capital Expenditures Growth (TTM) |
115.5 % |
25.78 % |
425.66 % |
217.38 % |
107.1 % |
Year on Year Capital Expenditures Growth Overall
Ranking |
# 187 |
# 816 |
# 1915 |
# 2386 |
# 438 |
Seqeuential Capital Expenditures Change (TTM) |
105.09 % |
-35.52 % |
14.12 % |
42.8 % |
19.7 % |
Seq. Capital Expenditures Growth (TTM) Overall
Ranking |
# 965 |
# 108 |
# 1735 |
# 1765 |
# 621 |
Cumulative Capital Expenditures growth
Comment |
Phathom Pharmaceuticals Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 115.5% year on year, to $ 2 millions if the fiscal year would have ended in Sep 30 2023. Phathom Pharmaceuticals Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 111.97% and higher than 25.78% growth in Jun 30 2023. But from twelve months ended Jun 30 2023 rise was less at 105.09 % from $0.77 millions recorded in twelve months ending a quarter before. There is stagnation in progress, more noticeable as we look at usual sequential historic increase which is stronger at111.97%. The growth was even more impressive from twelve months ended Jun 30 2023 showed at 105.09 % increase from $0.77 millions in twelve months ending a quarter Jun 30 2023.
In the Healthcare sector 43 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 187, from total ranking in previous quarter at 816. |
Capital Expenditures TTM Q/Q Growth Statistics |
High |
Average |
Low |
687.88 % |
111.97 % |
-68.46 % |
|
|
|
|
|
Capital Expenditures TTM Y/Y Growth Statistics |
High |
Average |
Low |
687.88 % |
111.97 % |
-68.46 % |
|
|
|
Capital Expenditures TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 50 |
Sector |
# 136 |
S&P 500 |
# 965 |
|
Cumulative Capital Expenditures growth
Comment |
Phathom Pharmaceuticals Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 115.5% year on year, to $ 2 millions if the fiscal year would have ended in Sep 30 2023. Phathom Pharmaceuticals Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 111.97% and higher than 25.78% growth in Jun 30 2023. But from twelve months ended Jun 30 2023 rise was beneth at 105.09 % from $0.77 millions achieved in twelve months ending a quarter before Nora Jansson added on. We witness slowdown developing, more obvious observing the average sequential historic increase that is stronger at111.97% Nora Jansson wrote. The growth is even stronger from the previous reporting period showed at 105.09 % jump from $0.77 millions in twelve months ending a quarter before.
In the Healthcare sector 43 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 187, from total ranking in previous quarter at 816. |
Capital Expenditures TTM Q/Q Growth Statistics |
High |
Average |
Low |
687.88 % |
111.97 % |
-68.46 % |
|
|
|
Capital Expenditures TTM Y/Y Growth Statistics |
High |
Average |
Low |
687.88 % |
111.97 % |
-68.46 % |
|
|
|
Capital Expenditures TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 50 |
Sector |
# 136 |
S&P 500 |
# 965 |
|